Neil E. Fleshner - Dec 22, 2023 Form 4 Insider Report for POINT Biopharma Global Inc. (PNT)

Role
Chief Medical Officer, Director
Signature
/s/ William L. Demers, by Power of Attorney for Neil E. Fleshner
Stock symbol
PNT
Transactions as of
Dec 22, 2023
Transactions value $
$0
Form type
4
Date filed
12/27/2023, 05:39 PM
Previous filing
Nov 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PNT Common Stock Disposition pursuant to a tender of shares in a change of control transaction -2.77M -100% 0 Dec 22, 2023 Direct F1
transaction PNT Common Stock Disposition pursuant to a tender of shares in a change of control transaction -233K -100% 0 Dec 22, 2023 1510789 Ontario Inc. F1, F2
transaction PNT Common Stock Disposition pursuant to a tender of shares in a change of control transaction -358 -100% 0 Dec 22, 2023 Trust Controlled by Wife F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PNT Stock Option (Right to Buy) Disposed to Issuer -25K -100% 0 Dec 27, 2023 Common Stock 25K $8.47 Direct F4
transaction PNT Stock Option (Right to Buy) Disposed to Issuer -60.2K -100% 0 Dec 27, 2023 Common Stock 60.2K $8.13 Direct F4
transaction PNT Stock Option (Right to Buy) Disposed to Issuer -84.3K -100% 0 Dec 27, 2023 Common Stock 84.3K $6.78 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Neil E. Fleshner is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.
F2 A corporation controlled by the Reporting Person.
F3 A trust, whose trustee is the Reporting Person's spouse.
F4 Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.